Can Pre-Surgery drug cocktail stop liver cancer from coming back?

NCT ID NCT05621499

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing whether giving a combination of drugs before surgery can reduce the risk of liver cancer returning in patients with a single, early-stage tumor that has a high chance of recurrence. Participants will receive either chemotherapy directly into the liver or a targeted therapy pill, both combined with an immunotherapy drug. The goal is to see if these pre-surgery treatments improve disease-free survival after the tumor is removed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of either chemotherapy infused into the liver (HAIC) or the targeted drug lenvatinib, plus the immunotherapy drug sintilimab
What this could lead to
If successful, this approach could lower the chance of liver cancer returning after surgery for patients at high risk.
What could go wrong
This is an early exploratory trial with only 60 participants, so results may not apply broadly. Combining treatments also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.